http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 04 Nov 2025 09:10:08 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Trading+Halts/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Trading+Halts/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0500 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Trading+Halts/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Trading+Halts/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0500 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Trading+Halts/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Trading+Halts/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0500 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Trading+Halts/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Trading+Halts/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0500 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Trading+Halts/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Trading+Halts/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0500 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Trading+Halts/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Trading+Halts/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0500 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Corporate+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Corporate+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0500 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Corporate+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Corporate+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0500 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Corporate+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Corporate+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0500 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Corporate+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Corporate+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0500 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Corporate+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Corporate+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0500 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Corporate+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Corporate+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0500 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Mergers+and+Acquisitions/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Mergers+and+Acquisitions/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0500 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Mergers+and+Acquisitions/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Mergers+and+Acquisitions/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0500 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Mergers+and+Acquisitions/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Mergers+and+Acquisitions/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0500 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Mergers+and+Acquisitions/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Mergers+and+Acquisitions/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0500 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Mergers+and+Acquisitions/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Mergers+and+Acquisitions/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0500 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Mergers+and+Acquisitions/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Mergers+and+Acquisitions/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0500 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Hot+Corp.+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Hot+Corp.+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0500 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Hot+Corp.+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Hot+Corp.+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0500 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Hot+Corp.+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Hot+Corp.+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0500 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Hot+Corp.+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Hot+Corp.+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0500 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Hot+Corp.+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Hot+Corp.+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0500 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Hot+Corp.+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Hot+Corp.+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0500 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Hot+M+and+A/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Hot+M+and+A/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0500 B MTSR NOVO NOVOB NVO PFE